Weill

Weill Cornell Medicine to Open Medical Research Center at 1334 York Avenue

Retrieved on: 
Tuesday, November 28, 2023
Research, Commercial Building & Real Estate, Nursing, Construction & Property, Hospitals, Practice Management, Managed Care, General Health, Health, Science, Medicine, DNA, Weill Cornell Medicine, Disease, Cornell University, Clinical trial, NewYork-Presbyterian Queens, Laboratory, Weill Cornell Medical Center, Patient, Multimedia, Regenerative medicine, Mining, Algorithm, Heart, Intelligence, Machine learning, Neuroscience, Blood, Houston Methodist Hospital, Sotheby's, Weill, Cancer, Population health, LEED, Biophysical environment, NewYork-Presbyterian Brooklyn Methodist Hospital, Immunotherapy, Physician, Certification, Education, Hospital, Pharmaceutical industry, NewYork-Presbyterian Hospital

Weill Cornell Medicine is dramatically expanding its campus and research footprint in New York City by securing five floors of 1334 York Ave., the current home of Sotheby's auction house, the institution announced today.

Key Points: 
  • Weill Cornell Medicine is dramatically expanding its campus and research footprint in New York City by securing five floors of 1334 York Ave., the current home of Sotheby's auction house, the institution announced today.
  • Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world.
  • The doctors and scientists of Weill Cornell Medicine—faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.
  • Weill Cornell Medicine faculty provide exemplary patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Westchester Behavioral Health Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital.

BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology

Retrieved on: 
Wednesday, July 7, 2021
Health care, Cornell University, Health, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill, TM

The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology.

Key Points: 
  • The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology.
  • To date, more than 50 physicians have completed over 1,000 patient cases with the PURE EP(tm) System across twelve clinical sites.
  • The Northeast is one of the three strategic areas that the Company is focused on in the targeted commercial launch phase.
  • BioSigs PURE EP(tm) technology was installed at New York Presbyterian / Weill Cornell Medical Center in New York, NY, one of the nations most comprehensive, integrated healthcare systems and New Yorks top-ranked hospital for 20 years1.

Weill Cornell Medicine Launches $1.5 Billion "We're Changing Medicine" Campaign with More Than $750 Million in Gifts

Retrieved on: 
Thursday, June 17, 2021
Cornell University, Tompkins County, New York, Satellite campuses, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Ivy League, Weill

Powering the We're Changing Medicine campaign is $215 million in foundational gifts from several of the institution's most longstanding benefactors.

Key Points: 
  • Powering the We're Changing Medicine campaign is $215 million in foundational gifts from several of the institution's most longstanding benefactors.
  • Choi, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University.
  • "This auspicious milestone will embolden Weill Cornell Medicine's distinguished doctors, researchers and trainees to continue their vital mission to change medicine."
  • "Weill Cornell Medicine exemplifies our mission to develop solutions that meet tomorrow's most pressing challenges, and the We're Changing Medicine campaign will ensure long-lasting advances in science and medicine."

Intellihealth Wins AmplifyHer Ventures Investment Competition at Weill Cornell Medicine

Retrieved on: 
Tuesday, May 4, 2021
Technology, Biotechnology, Health, Finance, Consumer, Pharmaceutical, Professional services, Telecommunications, Software, General Health, Hospitals, Internet, Women, Data management, Satellite campuses, Tompkins County, New York, Cornell University, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill, Ivy League, New York state), AmplifyHer Ventures, Intellihealth, AMPLIFYHER VENTURES, INTELLIHEALTH

The competition results were announced at the recent Weill Cornell Medicine Startup Symposium.\nA collaboration between AmplifyHer Ventures and the Weill Cornell Medicine BioVenture eLab, which is part of the Office of BioPharma Alliances and Research Collaborations, the investment competition was designed to highlight the exceptional women innovators at Weill Cornell Medicine and was open to companies across the health care and biopharma sectors that are affiliated with the academic medical institution and have women in key leadership roles.

Key Points: 
  • The competition results were announced at the recent Weill Cornell Medicine Startup Symposium.\nA collaboration between AmplifyHer Ventures and the Weill Cornell Medicine BioVenture eLab, which is part of the Office of BioPharma Alliances and Research Collaborations, the investment competition was designed to highlight the exceptional women innovators at Weill Cornell Medicine and was open to companies across the health care and biopharma sectors that are affiliated with the academic medical institution and have women in key leadership roles.
  • Intellihealth co-founder employee Dr. Katherine Saunders is an assistant professor of clinical medicine at Weill Cornell Medicine and was the first clinical fellow in obesity medicine at its Comprehensive Weight Control Center.\nDr.
  • \xe2\x80\x9cIn assessing the applicants, we immediately recognized that Intellihealth is accurately addressing a real market need.
  • More information and a product demonstration can be found at www.intellihealth.co .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005257/en/\n'

Weill Cornell Medicine Establishes Graduate Programs at Houston Methodist

Retrieved on: 
Friday, February 26, 2021
Satellite campuses, Cornell University, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill, Draft:Gunisha Kaur, James K. Min

NEW YORK and HOUSTON, Feb. 26, 2021 /PRNewswire/ -- In an expansion of its top-ranked biomedical education curricula, Weill Cornell Medicine is launching an additional site for graduate programs at Houston Methodist for the 2021-22 academic year.

Key Points: 
  • NEW YORK and HOUSTON, Feb. 26, 2021 /PRNewswire/ -- In an expansion of its top-ranked biomedical education curricula, Weill Cornell Medicine is launching an additional site for graduate programs at Houston Methodist for the 2021-22 academic year.
  • "This partnership between Weill Cornell Medicine and Houston Methodist allows us to broaden and enrich existing collaborations in research, education and clinical care between our two institutions," said Dr. Barbara Hempstead , dean of the Weill Cornell Graduate School of Medical Sciences and the O. Wayne Isom Professor of Medicine at Weill Cornell Medicine.
  • "We look forward to welcoming our first class of Weill Cornell Medicine doctoral candidates at Houston Methodist."
  • The doctors and scientists of Weill Cornell Medicinefaculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organizationare engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.

Weill Neurohub Joins Forces With Genentech and Roche to Advance Neuroscience Research

Retrieved on: 
Thursday, February 25, 2021
Research, Genetics, Other Health, Biotechnology, General Health, University, Pharmaceutical, Health, Science, Education, Carnegie Hall, Sanford I. Weill, Economy of the United States, Genentech, Philanthropy, Companies, Weill, University of California, Berkeley

The partnership, dubbed the Alliance for Therapies in Neuroscience (ATN), is a major milestone for the Weill Neurohub , a joint research collaboration between UCSF, UC Berkeley and the University of Washington.

Key Points: 
  • The partnership, dubbed the Alliance for Therapies in Neuroscience (ATN), is a major milestone for the Weill Neurohub , a joint research collaboration between UCSF, UC Berkeley and the University of Washington.
  • This represents a perfect opportunity to align the scientific expertise of our great public institutions with innovation that thrives at Genentech and Roche.
  • Our original vision was that the Weill Neurohub would partner with biotech and pharma companies to drive neuroscience research forward.
  • We thank Genentech and Roche for their commitment to not only prolonging life, but enhancing the quality of life for millions, said Weill Family Foundation President Joan Weill.

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

Retrieved on: 
Wednesday, February 3, 2021
Cornell University, Ivy League, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, NewYork-Presbyterian Hospital, Weill, Healthcare in New York City, New York state), James K. Min

"Scott is a leading scholar in the field of oncology medicine and research," commented Mr. Anthony Hayes, CEO of AIkido.

Key Points: 
  • "Scott is a leading scholar in the field of oncology medicine and research," commented Mr. Anthony Hayes, CEO of AIkido.
  • Dr. Tagawa is also the principle investigator for the targeted radiopharmaceutical therapy at Weil Cornell and his addition to our advisory board demonstrates our support for this innovative technology."
  • Dr. Scott T. Tagawa, MD, MS, FACP is a Professor of Medicine & Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian Weill Cornell Medical Center.
  • Subsequently, he underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years.

Jeffrey S. Borer, MD, is recognized by Continental Who's Who

Retrieved on: 
Friday, December 18, 2020
V-12 Navy College Training Program, Tompkins County, New York, NewYork–Presbyterian Healthcare System, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Cornell University, Weill, Ivy League

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Jeffrey S. Borer, MD, is being recognized by Continental Who's Who as a Prominent Professor for his remarkable contributions in the field of Medical Research and Education and in acknowledgment for his excellence in healthcare.

Key Points: 
  • NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Jeffrey S. Borer, MD, is being recognized by Continental Who's Who as a Prominent Professor for his remarkable contributions in the field of Medical Research and Education and in acknowledgment for his excellence in healthcare.
  • To prepare for his acclaimed career, Dr. Borer received his baccalaureate degree (in Government) from Harvard and his medical degree from Cornell University Medical College (now Weill Cornell Medicine).
  • The development allowed the unmasking of previously unapparent cardiac disabilities and quantifying their functional severity.
  • A respected voice in his field, Dr. Borer has published more than 500 full-length scientific papers/chapters and eight books.

EDAP Hosting Key Opinion Leader Call on Focal One® and ExactVu™

Retrieved on: 
Tuesday, September 15, 2020
V-12 Navy College Training Program, Tompkins County, New York, Kol, High-intensity focused ultrasound, Houston Methodist Hospital, Weill Cornell Medicine, Urology, Cornell University, Weill, Medicine, Ivy League

Call to be Held Tuesday, September 22nd @ 8am Eastern Time

Key Points: 
  • Call to be Held Tuesday, September 22nd @ 8am Eastern Time
    LYON, France, September 15, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will host a key opinion leader (KOL) call on its two lead commercial products, Focal One and ExactVu, on Tuesday, September 22nd at 8am Eastern Time.
  • The call will feature a presentation by Key Opinion Leaders (KOL) Brian Miles, MD (Houston Methodist) and Laurence Klotz, MD (Sunnybrook Health Sciences Centre) who will discuss the opportunity for the Focal One High Intensity Focused Ultrasound (HIFU) system and the ExactVu micro-ultrasound.
  • Miles is a Professor of Urology at Weill Cornell Medical College of Cornell University and Baylor College of Medicine.
  • Additionally, he is the Medical Director of Robotic Surgery at The Methodist Hospital and the physician in charge of Surgical Robot Training.

CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap

Retrieved on: 
Tuesday, May 5, 2020
V-12 Navy College Training Program, Tompkins County, New York, NewYork–Presbyterian Healthcare System, Ivy League, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Cornell University, Weill, New York state)

CareDx is collaborating with Weill Cornell Medicine on a multi-year research collaboration with exclusive rights to bring UroMap to patients.

Key Points: 
  • CareDx is collaborating with Weill Cornell Medicine on a multi-year research collaboration with exclusive rights to bring UroMap to patients.
  • UroMap developed by Dr. Manikkam Suthanthiran, a pioneer in molecular diagnostics and Chief of Nephrology, Hypertension and Transplantation Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, and his collaborators at Weill Cornell Medicine is an extensively studied technology including a study published in the New England Journal of Medicine .
  • We are delighted to announce this collaboration with Weill Cornell Medicine to help bring UroMaps rapid allograft rejection detection capabilities to our industry-leading suite of transplant care solutions, said Peter Maag, CEO of CareDx.
  • CareDx has obtained the exclusive rights to the UroMap technology through an exclusive license agreement with Cornell University, which was negotiated with Cornell Universitys technology transfer office, Center for Technology Licensing at Cornell University (CTL).